Key Points

  • An excellent outcome was obtained after allo-HCT in 712 patients with CGD, with a low incidence of graft failure and mortality.

  • HCT for CGD should be strongly considered in young patients, particularly in the presence of a well-matched donor.

Abstract

Chronic granulomatous disease (CGD) is a primary immunodeficiency resulting in life-threatening infections and inflammatory complications. Allogeneic hematopoietic cell transplantation (allo-HCT) can cure the disease, but the indication to transplant remains controversial. We performed a retrospective multicenter study of 712 patients with CGD who underwent allo-HCT transplantation from March 1993 through December 2018. We studied 635 children (aged <18 years) and 77 adults. Median follow-up was 45 months. Median age at transplantation was 7 years (range, 0.1-48.6). Kaplan-Meier estimates of overall survival (OS) and event-free survival (EFS) at 3 years were 85.7% and 75.8%, respectively. In multivariate analysis, older age was associated with reduced survival and increased chronic graft-versus-host disease. Nevertheless, OS and EFS at 3 years for patients ≥18 years were 76% and 69%, respectively. Use of 1-antigen-mismatched donors was associated with reduced OS and EFS . No significant difference was found in OS, but a significantly reduced EFS was noted in the small group of patients who received a transplant from a donor with a >1 antigen mismatch. Choice of conditioning regimen did not influence OS or EFS. In summary, we report an excellent outcome after allo-HCT in CGD, with low incidence of graft failure and mortality in all ages. Older patients and recipients of 1-antigen-mismatched grafts had a less favorable outcome. Transplantation should be strongly considered at a younger age and particularly in the presence of a well-matched donor.

REFERENCES

REFERENCES
1.
Seger
RA
.
Advances in the diagnosis and treatment of chronic granulomatous disease
.
Curr Opin Hematol
.
2011
;
18
(
1
):
36
-
41
.
2.
Thomsen
IP
,
Smith
MA
,
Holland
SM
,
Creech
CB
.
A Comprehensive Approach to the Management of Children and Adults with Chronic Granulomatous Disease
.
J Allergy Clin Immunol Pract
.
2016
;
4
(
6
):
1082
-
1088
.
3.
Jones
LB
,
McGrogan
P
,
Flood
TJ
, et al
.
Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry
.
Clin Exp Immunol
.
2008
;
152
(
2
):
211
-
218
.
4.
Liese
J
,
Kloos
S
,
Jendrossek
V
, et al
.
Long-term follow-up and outcome of 39 patients with chronic granulomatous disease
.
J Pediatr
.
2000
;
137
(
5
):
687
-
693
.
5.
Martire
B
,
Rondelli
R
,
Soresina
A
, et al;
IPINET
.
Clinical features, long-term follow-up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study
.
Clin Immunol
.
2008
;
126
(
2
):
155
-
164
.
6.
Cole
T
,
McKendrick
F
,
Titman
P
, et al
.
Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant
.
J Clin Immunol
.
2013
;
33
(
1
):
8
-
13
.
7.
Barlogis
V
,
Mahlaoui
N
,
Auquier
P
, et al
.
Burden of Poor Health Conditions and Quality of Life in 656 Children with Primary Immunodeficiency
.
J Pediatr
.
2018
;
194
:
211
-
217.e5
.
8.
Güngör
T
,
Teira
P
,
Slatter
M
, et al;
Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation
.
Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study
.
Lancet
.
2014
;
383
(
9915
):
436
-
448
.
9.
Morillo-Gutierrez
B
,
Beier
R
,
Rao
K
, et al
.
Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience [published correction appears in Blood. 2016;128(21):2585]
.
Blood
.
2016
;
128
(
3
):
440
-
448
.
6-03-704015
10.
Glucksberg
H
,
Storb
R
,
Fefer
A
, et al
.
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
.
Transplantation
.
1974
;
18
(
4
):
295
-
304
.
11.
Shulman
HM
,
Sullivan
KM
,
Weiden
PL
, et al
.
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients
.
Am J Med
.
1980
;
69
(
2
):
204
-
217
.
13.
Arnold
DE
,
Heimall
JR
.
A Review of Chronic Granulomatous Disease
.
Adv Ther
.
2017
;
34
(
12
):
2543
-
2557
.
14.
Dunogué
B
,
Pilmis
B
,
Mahlaoui
N
, et al
.
Chronic Granulomatous Disease in Patients Reaching Adulthood: A Nationwide Study in France
.
Clin Infect Dis
.
2017
;
64
(
6
):
767
-
775
.
15.
Seger
RA
,
Gungor
T
,
Belohradsky
BH
, et al
.
Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000
.
Blood
.
2002
;
100
(
13
):
4344
-
4350
.
16.
Yonkof
JR
,
Gupta
A
,
Fu
P
,
Garabedian
E
,
Dalal
J
;
the United States Immunodeficiency Network Consortium
.
Role of Allogeneic Hematopoietic Stem Cell Transplant for Chronic Granulomoatous Disease (CGD): a Report of the United States Immunodeficiency Network
.
J Clin Immunol
.
2019
;
39
(
4
):
448
-
458
.
17.
van den Berg
JM
,
van Koppen
E
,
Ahlin
A
, et al
.
Chronic granulomatous disease: the European experience
.
PLoS One
.
2009
;
4
(
4
):
e5234
.
18.
Parta
M
,
Kelly
C
,
Kwatemaa
N
, et al
.
Allogeneic reduced-intensity hematopoietic stem cell transplantation for chronic granulomatous disease: a single-center prospective trial
.
J Clin Immunol
.
2017
;
37
(
6
):
548
-
558
.
19.
Soncini
E
,
Slatter
MA
,
Jones
LB
, et al
.
Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth
.
Br J Haematol
.
2009
;
145
(
1
):
73
-
83
.
20.
Marsh
RA
,
Leiding
JW
,
Logan
BR
, et al;
submitted on behalf of the Primary Immune Deficiency Treatment Consortium
.
Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT
.
J Clin Immunol
.
2019
;
39
(
7
):
653
-
667
.
21.
Seger
RA
.
Modern management of chronic granulomatous disease
.
Br J Haematol
.
2008
;
140
(
3
):
255
-
266
.
22.
Vrooman
LM
,
Millard
HR
,
Brazauskas
R
, et al
.
Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age
.
Biol Blood Marrow Transplant
.
2017
;
23
(
8
):
1327
-
1334
.
23.
Leiper
A
,
Houwing
M
,
Davies
EG
, et al
.
Anti-Müllerian hormone and Inhibin B after stem cell transplant in childhood: a comparison of myeloablative, reduced intensity and treosulfan-based chemotherapy regimens [published online ahead of print 30 March 2020]
.
Bone Marrow Transplant
.
doi: 10.1038/s41409-020-0866-9
.
24.
Marsh
RA
,
Lane
A
,
Mehta
PA
, et al
.
Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT
.
Blood
.
2016
;
127
(
4
):
503
-
512
.
25.
Oostenbrink
LVE
,
Jol-van der Zijde
CM
,
Kielsen
K
, et al
.
Differential elimination of anti-thymocyte globulin of Fresenius and Genzyme impacts T-cell reconstitution after hematopoietic stem cell transplantation
.
Front Immunol
.
2019
;
10
:
315
.
26.
Bertaina
A
,
Merli
P
,
Rutella
S
, et al
.
HLA-haploidentical stem cell transplantation after removal of αβ+ T and B cells in children with nonmalignant disorders
.
Blood
.
2014
;
124
(
5
):
822
-
826
.
27.
Leick
M
,
Hunter
B
,
DeFilipp
Z
, et al
.
Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases
.
Bone Marrow Transplant
.
2020
;
55
(
4
):
758
-
762
.
28.
Lum
SH
,
Flood
T
,
Hambleton
S
, et al
.
Two decades of excellent transplant survival in children with chronic granulomatous disease: a supraregional immunology transplant center report
.
Blood
.
2019
;
133
(
23
):
2546
-
2549
.
29.
Balashov
D
,
Shcherbina
A
,
Maschan
M
, et al
.
Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRαβ and CD19 Depletion in Children with Primary Immunodeficiency Syndromes
.
Biol Blood Marrow Transplant
.
2015
;
21
(
11
):
1955
-
1962
.
30.
Kohn
DB
,
Booth
C
,
Kang
EM
, et al;
Net4CGD consortium
.
Lentiviral gene therapy for X-linked chronic granulomatous disease
.
Nat Med
.
2020
;
26
(
2
):
200
-
206
.
31.
De Ravin
SS
,
Li
L
,
Wu
X
, et al
.
CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease
.
Sci Transl Med
.
2017
;
9
(
372
):
eaah3480
.
You do not currently have access to this content.

Sign in via your Institution

Sign In